AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 4 - (NewsRx.com & NewsRx.net) -- Hormone replacement therapy (HRT) reduces RLP levels, although the MPA component inhibits the cardioprotective effects of estrogen.
According to recent research from Boston, HRT "in postmenopausal women has been shown to increase both triglyceride (TG) and high-density lipoprotein (HDL) cholesterol levels."
"To better understand the effects of conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA), the two most commonly prescribed hormones in HRT, on the different subpopulations of TG-rich and HDL lipoproteins," S. Lamon-Fava and coauthors at Tufts University "conducted a placebo-controlled, double-blind, randomized, crossover study consisting of three different phases in 14 postmenopausal women."
"The 3 phases, each 8-week long, included:
1) placebo,
2) CEE 0.625 mg/d, and
3) CEE 0.625 mg/d and MPA 2.5 mg/d," they wrote in the journal Metabolism - Clinical and Experimental.
Source: HighBeam Research, MPA component of HRT counteracts cardioprotective effects of estrogen.